Resverlogix Completes Enrollment in ASSURE Trial

Calgary, Alberta (ots/PRNewswire) -

IVUS data will evaluate plaque regression in patients with
Coronary Artery Disease

TSX Exchange Symbol: RVX

Resverlogix Corp. today announced that it has completed
enrollment in ASSURE, a Phase 2b clinical trial targeting high-risk
cardiovascular disease patients. ASSURE will evaluate the ability of
RVX-208, Resverlogix's BET protein inhibitor, to regress
atherosclerotic disease versus placebo using intravascular ultrasound
(IVUS) technology in patients with coronary artery disease (CAD).

"Completing enrollment of the ASSURE clinical trial marks another
major milestone for Resverlogix as we aim to demonstrate the efficacy
of RVX-208 in atherosclerotic plague regression," stated Donald
McCaffrey, president and chief executive officer of Resverlogix.
"RVX-208 stimulates production of ApoA-I, increasing the functional
HDL particles required for reverse cholesterol transport. We expect
to announce top-line data from ASSURE in H1 2013."

ASSURE is a 26-week, multi-center, double-blind, randomized,
parallel group, placebo-controlled clinical trial led by the
Cleveland Clinic. The primary trial endpoint will be measurement of
atheroma volume reduction from baseline to 26 weeks measured by IVUS.
Secondary objectives for ASSURE are evaluating the safety and
tolerability of RVX-208 and effects of RVX-208 on HDL and non-HDL
lipid parameters. Using IVUS data, we will also assess changes in
plaque stability, an important factor affecting risk of myocardial
infarction.

About RVX-208

RVX-208 is a first-in-class, small molecule that inhibits BET
bromodomains. It is currently in clinical study for the treatment of
atherosclerosis. RVX-208 functions by removing atherosclerotic plaque
via reverse cholesterol transport (RCT), the natural process through
which atherosclerotic plaque is transported out of the arteries and
removed from the body by the liver. RVX-208 increases production of
ApoA-I, the key building block of functional high-density lipoprotein
(HDL) particles and the type required for RCT. Because they are newly
produced, these functional HDL particles are flat and empty and can
efficiently remove plaque and stabilize or reverse atherosclerotic
disease. RVX-208 is currently being evaluated in phase 2b studies for
its ability to reverse and/or stabilize atherosclerotic disease. The
drug candidate also has the potential to treat other indications,
including neurodegenerative disorders.

About Resverlogix

Resverlogix Corp. is a clinical stage cardiovascular company
with an epigenetic platform technology that modulates protein
production. Resverlogix is developing RVX-208, a first-in-class small
molecule for the treatment of atherosclerosis. RVX-208 is the first
BET bromodomain inhibitor in clinical trials. New compounds arising
from Resverlogix's epigenetic drug discovery platform function by
inhibiting BET bromodomains and have the potential to impact multiple
diseases including cancer, autoimmune and neurodegenerative
disorders. Resverlogix's common shares trade on the Toronto Stock
Exchange . For further information please visit
http://www.resverlogix.com.

This news release may contain certain forward-looking information
as defined under applicable Canadian securities legislation, that are
not based on historical fact, including without limitation statements
containing the words "believes", "anticipates", "plans", "intends",
"will", "should", "expects", "continue", "estimate", "forecasts" and
other similar expressions. In particular, this news release includes
forward looking information relating to research and development
activities and the potential role of RVX-208 in the treatment of
atherosclerosis. Our actual results, events or developments could be
materially different from those expressed or implied by these
forward-looking statements. We can give no assurance that any of the
events or expectations will occur or be realized. By their nature,
forward-looking statements are subject to numerous assumptions and
risk factors including but not limited to those associated with the
success of research and development programs, clinical trial programs
including possible delays in patient recruitment, the regulatory
approval process, competition, securing and maintaining corporate
alliances, market acceptance of the Company's products, the
availability of government and insurance reimbursements for the
Company's products, the strength of intellectual property, financing
capability, the potential dilutive effects of any financing, reliance
on subcontractors and key personnel and additional assumptions and
risk factors discussed in our Annual Information Form and most recent
MD&A which are incorporated herein by reference and are available
through SEDAR at http://www.sedar.com. The forward-looking statements
contained in this news release are expressly qualified by this
cautionary statement and are made as of the date hereof. The Company
disclaims any intention and has no obligation or responsibility,
except as required by law, to update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise.

For further information, please contact:

Company Contacts:

Donald J. McCaffrey
President and CEO
Resverlogix Corp.
Phone: +1-403-254-9252
e-mail: don@resverlogix.com

US Institutional Investors:

Susan Noonan
Managing Partner
S.A. Noonan Communications, LLC
Phone: +1-212-966-3650
e-mail: susan@sanoonan.com

Sarah Zapotichny
Director of Investor Relations
Resverlogix Corp.
Phone: +1-403-254-9252
e-mail: sarah@resverlogix.com

Media:

Matt Middleman, M.D.
Russo Partners, LLC
Phone: +1-212-845-4272
e-mail: matt.middleman@russopartnersllc.com

ots Originaltext: Resverlogix Corp.
Im Internet recherchierbar: http://www.presseportal.de